<DOC>
	<DOC>NCT01509391</DOC>
	<brief_summary>In this study the investigators examine the safety and efficacy of Keyhole-limpet-hemocyanin in patients with chronic hepatitis c infection and liver cirrhosis. The investigators hypothesize that administration of keyhole-limpet-hemocyanin reduces the viral load in patients infected with hepatitis c.</brief_summary>
	<brief_title>Keyhole Limpet Hemocyanin in Chronic Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Keyhole-limpet hemocyanin</mesh_term>
	<criteria>Chronic Hepatitis C infection no previous therapy at least one contraindication to interferon therapy liver cirrhosis age between 1880 y women of not childbearing age Hypersensitivity against keyholelimpet hemocyanin previous treatment against hepatitis c autoimmune disorders immunosuppression hepatocellular carcinoma or other malignancies coinfection with hepatitis b or HIV pregnancy cardiovascular event during the last 6 months (stroke or MCI) uncontrolled diabetes renal insufficiency (GFR &lt; 50 ml/min) or chronic hemodialysis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2012</verification_date>
</DOC>